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Background
Plexiform lesions are a hallmark of severe pulmonary
arterial hypertension (PAH) and despite the develop-
ment of novel therapeutics approaches, the prognosis of
patients with PAH is relatively poor. Riociguat is a sti-
mulator of soluble guanylate cyclase (sGC) which has a
dual mode of action: it sensitizes sGC to the body’so w n
NO and can also increase sGC activity in the absence of
NO, causing vasorelaxation, anti-proliferation and anti-
fibrotic effects. This is thought to be important because
the NO levels in the pulmonary circulation are
decreased in patients with PAH.
The aim of the study was to investigate the effects of
riociguat as compared to the PDE5 inhibitor sildenafil
on pulmonary vascular remodeling in severe experimen-
tal PH.
Methods
Angioproliferative pulmonary hypertension was induced
in rats by combined exposure to the vascular endothelial
growth factor-receptor (VEGFr) antagonist SU5416 and
hypoxia at 10%O2 (SU+HOX). Twenty-one days after
SU+HOX, rats were randomized for oral treatment with
riociguat (10 mg/kg BW/day), sildenafil (50 mg/kg BW/
day) or vehicle for the next 14 days. Right ventricular
internal diameter (RVID), tricuspid annular plane systo-
lic excursion (TAPSE) and myocardial performance
index (MPI) were measured by echocardiography
(VEVO770, Visualsonics). Hemodynamic parameters
were measured invasively at day 35. Pulmonary vascular
remodeling was assessed by histomorphometric analysis
of the degree of muscularization of small pulmonary
arteries.
Results
In rats with established PH, right ventricular systolic
pressure (RVSP) was significantly decreased by treat-
ment with riociguat to 73±4 mmHg (p=0.01) and silde-
nafil to 80±3 mmHg (p<0.05) as compared to placebo
(89±3 mmHg). Riociguat, but not sildenafil markedly
increased cardiac output (CO) to 60±5 ml/min (p<0.01)
as compared with placebo (31±3 ml/min). Both, rioci-
guat and sildenafil significantly decreased total pulmon-
ary resistance index (p<0.001). Importantly, no
significant difference in systemic arterial pressure (SAP)
was detected between placebo and treated animals.
These positive hemodynamic responses to riociguat and
sildenafil were associated with partial reversal of struc-
tural remodeling of the lung vasculature. Additionally
riociguat significantly reduced the proportion of
occluded arteries and increased proportion of opened
arteries and significantly decreased the neointima/media
ratio. In addition, riociguat significantly decreased ratio
of RV to LV+S to 0.55±0.29 as compared to placebo
(0.76±0.02, p<0.001) and sildenafil treated animals (0.66
±0.29, p<0.01). Moreover, riociguat improved RV func-
tion by normalization of TAPSE as compared to placebo
(p<0.001) and sildenafil (p<0.05). Both compounds
improved MPI measured by tissue Doppler imaging
(p<0.001).
Conclusion
We demonstrated that riociguat effectively suppresses
pulmonary vascular remodeling and significantly
improves RV function, measured via a range of invasive
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